Evidence map›Paper›PMID 26644412›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2016

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Katherine Tarlock, Todd A Alonzo, Robert B Gerbing, Susana C Raimondi, Betsy A Hirsch, Lillian Sung, Jessica A Pollard, Richard Aplenc, Michael R Loken, Alan S Gamis and 1 more

Open access · bronzeAbstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in PediatricJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 2 countries.

Katherine TarlockDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington. ktarlock@fredhutch.org.
Todd A AlonzoKeck School of Medicine, University of Southern California, Los Angeles, California.
Robert B GerbingDepartment of Statistics, Children's Oncology Group, Monrovia, California.
Susana C RaimondiDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Betsy A HirschLaboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota.
Lillian SungDivision of Haematology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Jessica A PollardMaine Children's Cancer Program, Maine Medical Center, Scarborough, Maine.
Richard AplencPediatric Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Michael R LokenHematologics Incorporated, Seattle, Washington.
Alan S GamisHematology/Oncology, Children's Mercy Hospitals and Clinics, Kansas City, Missouri.
Soheil MeshinchiDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Fred Hutch Cancer Center · USAnthem (United States) · USChildren's Hospital of Philadelphia · USChildren's Mercy Hospital · USChildren's Oncology Group · USHospital for Sick Children · CAMaine Medical Center · USSt. Jude Children's Research Hospital · USUniversity of Minnesota Medical Center · USUniversity of Southern California · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5M
PEDIATRIC ONCOLOGY RESEARCH TRAINING PROGRAMT32CA009351 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth R Lawlor, SOHEIL MESHINCHI · 1985 to 2026
$7.0M
NCI NIH HHS T32 CA009351NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U10 CA98413NCI NIH HHS U10 CA98543
6 · The paper itself

Abstract

purposeGemtuzumab ozogamicin (GO), a calicheamicin-conjugated mAb against CD33, has been used in the treatment of acute myeloid leukemia (AML). We evaluated the impact of the addition of GO to standard chemotherapy and hematopoietic stem cell transplant (HCT) in patients withFLT3/ITD. EXPERIMENTAL

designWe analyzed children withFLT3/ITD-positive AML (n= 183) treated on two consecutive Children's Oncology Group AML trials (NCT00070174andNCT00372593). Outcomes were assessed forFLT3/ITD patients receiving standard chemotherapy with or without GO (GO vs. No-GO, respectively), and the impact of consolidation HCT for high-riskFLT3/ITD patients [highFLT3/ITD allelic ratio (ITD-AR)].

resultsFor allFLT3/ITD patients, complete remission (CR) rates for the GO versus No-GO cohorts were identical (64% vs. 64%;P= 0.98). Relapse rate (RR) after initial CR was 37% for GO recipients versus 59% for No-GO recipients (P= 0.02), disease-free survival (DFS) was similar (47% vs. 41%;P= 0.45), with higher treatment-related mortality (TRM) in GO recipients (16% vs. 0%;P= 0.008). Among high-riskFLT3/ITD patients with high ITD-AR, those who received HCT in first CR with prior exposure to GO had a significant reduction in RR (15% vs. 53%;P= 0.007), with a corresponding DFS of 65% versus 40% (P= 0.08), and higher TRM (19% vs. 7%;P= 0.08).

conclusionsCD33 targeting with HCT consolidation may be an important therapeutic strategy in high-riskFLT3/ITD AML and its efficacy and associated toxicity warrant further investigation.

Indexed as

Gene DuplicationAdolescentAdultAminoglycosidesAntibodies, Monoclonal, HumanizedAntineoplastic AgentsChildChild, PreschoolFemalefms-Like Tyrosine Kinase 3Follow-Up StudiesGemtuzumabHematopoietic Stem Cell TransplantationHumansInfantInfant, NewbornAminoglycosidesAntibodies, Monoclonal, HumanizedAntineoplastic Agentsfms-Like Tyrosine Kinase 3Gemtuzumab

Identifiers

PMID26644412
PMCPMC4834220
OpenAlexW2191511762

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.